Waters Report 8% Revenue Increase
News Jan 28, 2014
In the quarter, sales grew 10% before the effects of foreign currency translation. On a GAAP basis, earnings per diluted share (E.P.S.) for the fourth quarter were $1.65 compared to $2.00 for the fourth quarter of 2012. On a non-GAAP basis, including the adjustments in the attached reconciliation, E.P.S. grew 7% to $1.70from $1.59 in the fourth quarter of 2012.
For the full year, sales for the Company were $1.90 billion, an increase of 3% in comparison to sales of $1.84 billion in 2012, with foreign currency translation reducing sales growth by about 2%. E.P.S. for 2013 were $5.20compared to $5.19 in 2012. On a non-GAAP basis, including adjustments in the attached reconciliation, E.P.S. grew 2% to $5.04 from $4.93 in 2012.
Commenting on the Company’s 2013 performance, Douglas Berthiaume, Chairman, President and Chief Executive Officer said, “A strong fourth quarter sales result brought our full-year 2013 constant currency sales growth to 5%. Through the year, the growth in our operating income was materially and adversely affected by foreign currency translation, principally the weaker Japanese yen. The strength in the fourth quarter of 2013 was broad based in terms of our key product lines and business segments and was highlighted by improved pharmaceutical demand accompanied by continued strength in global academic and industrial chemical end markets.”
Chinese researchers have developed interfacially polymerized porous polymer particles for low- abundance glycopeptide separation. These polymer particles - with hydrophilic-hydrophobic heterostructured nanopores - can separate low-abundance glycopeptides from complex biological samples with high-abundance background molecules efficiently.